Bicara Therapeutics
Zhao (Tony) Yang, Ph.D., is an experienced biostatistician currently serving as Senior Director of Biostatistics at Bicara Therapeutics since January 2025. Prior to this role, Zhao held the position of Senior Director of Biostatistics at Keros Therapeutics for a brief period in late 2024 and served in various senior roles at HUTCHMED from October 2020 to July 2024, including Director of Biostatistics. Zhao's expertise spans significant leadership positions at Everest Clinical Research, G1 Therapeutics, Synteract, and UCB, with earlier experience at IQVIA and Premier Research. Educational credentials include a Ph.D. in Biostatistics from the University of South Carolina, a Master of Medicine from Shanghai Medical College of Fudan University, and an MBBS from China Medical University.
This person is not in any teams
This person is not in any offices
Bicara Therapeutics
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.